Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

NCT02054104 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

21

Enrollment

NIH

Sponsor class

Stopped Vaccine production halted in 2015, thus study is terminated.

Conditions

Thoracic Sarcomas
Thorasic Cancers
Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Sarcoma
Melanoma

Interventions

BIOLOGICAL: H1299 cell lysates
DRUG: Cyclophosphamide
DRUG: Celecoxib
BIOLOGICAL: Iscomatrix adjuvant

Sponsor

National Cancer Institute (NCI)